# US 2012/0237472 A1 · Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0237472 A1
- Document ID: US20120237472A1
- Status: Published application
- Kind: A1
- Application number: 13/386,730
- Filed: 2010-07-23
- Published: 2012-09-20
- Earliest claimed: 2009-07-24
- Assignees: The Johns Hopkins University
- Inventors: Adam Ian Kaplin; Mark T. Worthington
- Web page: https://patentgrep.com/patent/US20120237472A1

## CPC

- A61K 31/67: having sulfur as a ring hetero atom
- A61K 31/66: Phosphorus compounds
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 38/1709: {from mammals}
- A61K 39/39541: {against normal tissues, cells}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 5/38: of the suprarenal hormones
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compositions and methods for treating and/or preventing an autoimmune disease comprising administering to a subject in need thereof an effective amount of cyclophosphamide and/or a cyclophosphamide derivative in combination with an additional immunomodulatory agent.

## Claims

### Claim 1

A method for treating or preventing an autoimmune disease, the method comprising administering to a subject in need thereof:
a) a lymphablative agent selected from the group consisting of cyclophosphamide and a cyclophosphamide derivative; and
b) an additional immunomodulatory agent selected from the group consisting of an amino acid co-polymer, a peptide fragment of myelin basic protein, an anti-tumor necrosis factor agent and pharmaceutically acceptable salts thereof;
wherein the autoimmune disease selected from the group consisting of inflammatory bowel disease, rheumatoid arthritis, diabetes mellitus, celiac disease, autoimmune thyroid disease, autoimmune liver disease, Addison's Disease, Sjögren's Syndrome, transplant rejection, graft vs. host disease and host vs. graft disease.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein the lymphablative agent is a cyclophosphamide derivative selected from the group consisting of: 4-hydroperoxycyclophosphamide, mafosfamide, 4-hydroxycyclophosphamide, aldophosphamide and 4-(S-alkyl)cyclophosphamide.

### Claim 4 (depends on 1)

The method of claim 1, wherein the autoimmune disease is inflammatory bowel disease selected from the group consisting of inflammatory bowel disease, rheumatoid arthritis, diabetes mellitus, celiac disease, autoimmune thyroid disease, autoimmune liver disease, Addison's Disease, Sjögren's Syndrome, transplant rejection, graft vs. host disease, host vs. graft disease, multiple sclerosis, Guillain-Barre syndrome, Lambert-Eaton myasthenic syndrome, myasthenia gravis, transverse myelitis, systemic lupus erythematosus (SLE or lupus), acute disseminated encephalomyelitis, autoimmune inner ear disease, narcolepsy, neuromyotonia, or schizophrenia.

### Claim at position 5

-6. (canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the lymphablative agent is administered at an amount effective to achieve immune lymphablation in the subject.

### Claim at position 7

-11. (canceled)

### Claim 12 (depends on 1)

The method of claim 1, further comprising administering to the subject an anti-lymphocyte antibody.

### Claim 13 (depends on 12)

The method of claim 12, wherein the anti-lymphocyte antibody is administered in an amount that is effective to reduce the number of T cells in the subject.

### Claim 14

(canceled)

### Claim 15 (depends on 12)

The method of claim 12, wherein the anti-lymphocyte antibody is administered concurrently with or subsequent to the administration of the lymphablative agent.

### Claim 16

(canceled)

### Claim 17 (depends on 12)

The method of claim 12, wherein the anti-lymphocyte antibody is anti-CD3 antibody, anti-CD4 antibody, anti-CD8 antibody, anti-lymphocyte serum, an anti-natural killer cell antibody, or an anti-CD40L antibody.

### Claim 18 (depends on 1)

The method of claim 1, wherein the additional immunomodulatory agent is an amino acid co-polymer or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein the amino acid co-polymer is a YEAK, VWAK, FYAK, YFAK, or VYAK co-polymer.

### Claim at position 16

-25. (canceled)

### Claim 26 (depends on 1)

The method of claim 1, wherein the additional immunomodulatory agent is a peptide fragment of myelin basic protein or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 26)

The method of claim 26, wherein the peptide fragment of myelin basic protein is:
(SEQ ID NO: 2)
Asp-Glu-Asn-Pro-Val-Val-His-Phe-Phe-Lys-Asn-Ile-
Val-Thr-Pro-Arg-Thr;
(SEQ ID NO: 3)
Lys-Ser-His-Gly-Arg-Thr-Gln-Asp-Glu-Asn-Pro-Val-
Val-His-Phe-Phe-Lys-Asn-Ile-Val-Thr;
(SEQ ID NO: 4)
Ala-Arg-Thr-Ala-His-Tyr-Gly-Ser-Leu-Pro-Gln-Lys-
Ser-His-Gly;
(SEQ ID NO: 5)
His-His-Pro-Ala-Arg-Thr-Ala-His-Tyr-Gly-Ser-Leu-
Pro-Gln-Lys;
(SEQ ID NO: 6)
Tyr-Gly-Ser-Leu-Pro-Gln-Lys-Ser-His-Gly-Arg-Thr-
Gln-Asp-Glu;
(SEQ ID NO: 7)
Thr-Gln-Asp-Glu-Asn-Pro-Val-Val-His-Phe-Phe-Lys-
Asn-Ile-Val-Thr-Pro-Arg;
(SEQ ID NO: 8)
Lys-Asn-Ile-Val-Thr-Pro-Arg-Thr-Pro-Pro-Pro-Ser-
Gln-Gly-Lys-Gly;
(SEQ ID NO: 9)
Asn-Pro-Val-Val-His-Phe-Phe-Lys-Asn-Ile;
(SEQ ID NO: 10)
Pro-Val-Val-His-Phe-Phe-Lys-Asn-Ile-Val;
(SEQ ID NO: 11)
Val-Val-His-Phe-Phe-Lys-Asn-Ile-Val-Thr;
or
(SEQ ID NO: 12)
Val-His-Phe-Phe-Lys-Asn-Ile-Val-Thr-Pro.

### Claim at position 19

-32. (canceled)

### Claim 33 (depends on 1)

The method of claim 1, wherein the additional immunomodulatory agent is an anti-tumor necrosis factor agent.

### Claim 34 (depends on 33)

The method of claim 33, wherein the anti-tumor necrosis factor agent is infliximab, adalimumab, certolizumab, or golimumab.

### Claim at position 22

-38. (canceled)

### Claim 39 (depends on 1)

The method of claim 1, further comprising administering an effective amount of granulocyte colony stimulating factor.

### Claim 40 (depends on 1)

The method of claim 1, further comprising administering an effective amount of an antibiotic.

### Claim at position 25

-64. (canceled)

### Claim 65 (depends on 1)

The method of claim 1, further comprising administering vitamin D to the subject.

### Claim at position 27

-141. (canceled)

### Claim 142

A composition comprising (a) an effective amount of cyclophosphamide or a cyclophosphamide derivative; and (b) an additional immunomodulatory agent selected from the group consisting of an amino acid co-polymer, a peptide fragment of myelin basic protein, an anti-tumor necrosis factor agent, an anti-lymphocyte antibody and pharmaceutically acceptable salts, solvates and isomers thereof, in an effective amount to prevent or treat an autoimmune disease in a subject.

### Claim 143 (depends on 142)

The composition of claim 142, wherein the composition comprises a cyclophosphamide derivative selected from the group consisting of 4-hydroperoxycyclophosphamide, mafosfamide, 4-hydroxycyclophosphamide, aldophosphamide and 4-(S-alkyl)cyclophosphamide.

### Claim 144

(canceled)

### Claim 145 (depends on 142)

The composition of claim 142, further comprising administering to the subject an anti-lymphocyte antibody.
